Analyze Publications Database

Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial

Smith SR, Stenlof KS, Greenway FL, McHutchison J, Schwartz SM, Dev VB, Berk ES, Kapikian R. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. Obesity (Silver Spring). September 2011;19(9):1796-1803.

Full Text – Open Access

Publication Date
September 2011

How Analyze was Used
“All CT scans were transferred and analyzed at one site (Pennington Biomedical Research Center) using commercially available software (Analyze; AnalyzeDirect).”

Keywords
Adiposity/drug effects
Adult
Anti-Obesity Agents/administration & dosage/adverse effects/therapeutic use
Body Mass Index
Combined Modality Therapy
Diet, Reducing
Double-Blind Method
Enzyme Inhibitors/administration & dosage/adverse effects/therapeutic use
Female
Humans
Intra-Abdominal Fat/drug effects/radiography
Lactones/administration & dosage/adverse effects/therapeutic use
Lipase/antagonists & inhibitors
Liver/drug effects/radiography
Male
Middle Aged
Muscles/drug effects/radiography
Overweight/diet therapy/drug therapy/pathology
Time Factors
Tomography, X-Ray Computed
Weight Loss/drug effects

Author Affiliation(s)
BioImaging, Pennington Biomedical Research Center, Baton Rouge, LA, US. (SRS)

Stenlöf Department of Clinical Research, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden. (KSS)

Clinical Trials, Pennington Biomedical Research Center, Baton Rouge, LA, US. (FLG)

Department of Medicine, Duke Clinical Research Unit, Durham, NC, US. (JM)

GlaxoSmithKline Consumer Healthcare, Parsippany, NJ, US. (SMS, RK)

ID# 780

Tags: , , , , , , , , , , , , , , , , , , , ,